Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Your search for supplemental oxygen returned 10 results
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.
The Food and Drug Administration has cleared the initiation of a phase 3 trial evaluating INOpulse® inhaled nitric oxide (iNO) therapy (Bellerophon Therapeutics) in patients with coronavirus disease 2019 (COVID-19).
The update was based on data from the COV-BARRIER study.
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
The use of e-cigarette products has been associated with several cases of severe pulmonary disease, according to the Centers for Disease Control and Prevention (CDC). In an official health advisory, the CDC stated that 215 possible cases have been reported across 25 states, with additional suspected cases still under investigation. One death has also been…
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
Sarilumab is currently marketed under the brand name Kevzara for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to 1 or more disease-modifying antirheumatic drugs.
Updated on 6/16 While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.* AB201 (ARCA biopharma): a selective inhibitor of tissue factor being developed as a potential treatment for COVID associated coagulopathy. Clinical testing is expected to begin in the second half of 2020. Acalabrutinib (AstraZeneca): a…